Investigating the efficacy of Donanemab in early symptomatic Alzheimer’s disease (TRAILBLAZER 2)

Occurring Dates
to
Participant Duration
One clinic visit per month across 18 months
State of study
Victoria
Overview

This study is aimed at investigating the safety and efficacy of Donanemab in treating or delaying the progression of Alzheimer’s disease. On meeting the eligibility criteria, participants will be randomised to receive either Donanemab or placebo. The study will involve attending approximately 18-20 clinic visits at the Royal Melbourne Hospital across a 76-week (18-month) period.

You may be eligible if:

  • You are between 60 and 85 years of age inclusive
  • There has been gradual and progressive change in memory function for 6 months or longer
  • You have received a diagnosis of Mild Cognitive Impairment (MCI) or mild / early stage Alzheimer’s disease
  • You have a carer / study partner that can accompany you to the study visits
Further information

For further information or to participate, please contact Dr Essie Low on (03) 9342 8678 or at [email protected].

This study has been approved by Melbourne Health Human Research Ethics Committee (reference number: 2021.066).

Study Address
Royal Melbourne Hospital - City Campus
300 Grattan Street Parkville Vic 3050
Full Name
Dr Essie Low, Dementia Research Manager
Institute
Neurology, Royal Melbourne Hospital
Phone Number
(03) 9342 8678